NETTER-2: Lu-177 Dotatate for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors

Patients with metastatic colorectal cancer who received frontline immune checkpoint inhibitor therapy had positive OS rates and durable responses vs chemotherapy alone.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Following promising phase 1 data, TCMCB07 is being further evaluated in a phase 2 trial for the treatment of patients with stage IV colorectal cancer.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular carcinoma

The primary end point of overall response rate has been met in the COMPANION-002 trial of tovecimig and paclitaxel in advanced biliary tract cancer.